SBBP Strongbridge Biopharma

Strongbridge Biopharma plc to Present at Upcoming 2020 Solebury Trout Virtual Global Healthcare Conference Series

Strongbridge Biopharma plc to Present at Upcoming 2020 Solebury Trout Virtual Global Healthcare Conference Series

DUBLIN, Ireland and TREVOSE, Pa., May 18, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the management team will present at the upcoming Solebury Trout Virtual Global Healthcare Conference Series. Details are as follows:

Date/Time: Tuesday, May 26, 2020 at 12:00 p.m. EDT

To access the presentation, please login here:

The Company’s presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at .

About Strongbridge Biopharma

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:

Corporate and Media Relations

Elixir Health Public Relations

Lindsay Rocco



Investor Relations

Solebury Trout

Mike Biega



EN
18/05/2020

Underlying

SBBPStrongbridge Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strongbridge Biopharma

 PRESS RELEASE
Free
SBBP Strongbridge Bi...

Strongbridge Biopharma plc Announces Completion of Acquisition by Xeri...

Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc. DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The Court sanction hearing in relation t...

October 5, 2021 1 EN
 PRESS RELEASE
Free
SBBP Strongbridge Bi...

Strongbridge Biopharma plc Announces Court Hearing Date to Approve Pro...

Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc. DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the “Court”) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (“Xeris”) by means of scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”). The court h...

September 23, 2021 1 EN
 PRESS RELEASE
Free
SBBP Strongbridge Bi...

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed ...

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc. DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “Court Meeting”) and at an extraordinar...

September 8, 2021 1 EN
 PRESS RELEASE
Free
SBBP Strongbridge Bi...

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends ...

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals DUBLIN, Ireland and TREVOSE, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”) today announced that Glass Lewis & Co. (“Glass Lewis”) has recommended that Strongbridge shareholders vote “FOR” all proposals related to t...

August 31, 2021 1 EN
 PRESS RELEASE
Free
SBBP Strongbridge Bi...

Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Bi...

Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals DUBLIN, Ireland and TREVOSE, Pa., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”) today announced that the leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Strongbridge shareholders vote “FOR” the Company’s transaction with Xeris Pharmaceuticals (Nasdaq: XERS) (“Xeris”). In it...

August 30, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch